Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
EVALUATION OF THE EFFICACY AND SAFETY FOR CHRONIC HEPATITIS C TREATED WITH ELBASVIR/GRAZOPREVIR
- At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
- Type: Poster
- By: TSAI, Tzu-Cheng (Chang Gung Memorial Hospital, Pharmacy, China Taiwan)
- Co-author(s): Tzu-Cheng Tsai: Pharmacy, Chang Gung Memorial Hospital, China Taiwan
Hui-Yu Chen: Pharmacy, Chang Gung Memorial Hospital, China Taiwan
Shin-Tarng Deng: Pharmacy, Chang Gung Memorial Hospital, China Taiwan
Chao-Wei Hsu: Gastroenterology and Hepatology, Chang Gung Memorial Hospital, China Taiwan
BackgroundElbasvir/grazoprevir (EBR/GZR) is a new generation, fixed-dose, combination antiviral drug used in chronic hepatitis C virus (HCV) genotype (GT) 1 or 4 infection.
MethodsThis is a retrospective observational study. Patients were recruited who had received EBR/GZR for chronic HCV GT 1 between June 2017 and April 2018. Patients’ age, sex,.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 13 May 2019